Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | DRD4 | P21917 | 5/20 | 0.40 |
| ▸ | HTR1B | P28222 | 5/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | USP1 | O94782 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809414 | 0.91 | HTR1A (0.42) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL23809281 | 0.87 | MCL1 (0.42) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL23809336 | 0.86 | ICMT (0.38) | HTR1ADRD4HTR1BDRD3HTR7 | |
| SCHEMBL23809288 | 0.84 | MCL1 (0.43) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL23809455 | 0.84 | DRD2 (0.38) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL23809423 | 0.83 | MCL1 (0.42) | DRD2HTR2AICMTMCL1 | |
| SCHEMBL23809334 | 0.78 | KDR (0.37) | HTR1ADRD4HTR1BDRD3ICMT | |
| SCHEMBL23809218 | 0.78 | DRD2 (0.42) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL23809214 | 0.78 | MCL1 (0.41) | MCL1 | |
| SCHEMBL20604925 | 0.78 | HTR1A (0.42) | DRD2HTR2AHTR1ADRD4HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | DRD2 3801/4885HTR2A 1729/4885HTR1A 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.